NEDD8-conjugating enzyme E2s: critical targets for cancer therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• NEDD8-conjugating enzymes, E2s, include UBE2M and UBE2F.
• These enzymes are crucial for neddylation of Cullin and non-Cullin substrates.
• Overexpression of UBE2M and UBE2F is linked to poor survival in various malignancies.

Purpose of the Study:

• To review the roles of UBE2M and UBE2F in tumor progression.
• To highlight their potential as anti-tumor therapeutic targets.
• To explore strategies for targeting these enzymes in cancer treatment.

Main Methods:

• Literature review of recent advances in UBE2M and UBE2F research.
• Analysis of their roles in cancer cell biology, including DNA-damage response, apoptosis, and anti-tumor immunity.
• Examination of therapeutic strategies targeting UBE2M and UBE2F.

Main Results:

• UBE2M modulation impacts tumor growth via biological responses and anti-tumor immunity.
• Inhibitors targeting UBE2M-DCN1 interaction show anti-tumor effects.
• UBE2F inhibition can trigger apoptosis, suggesting a role in chemo-/radiosensitization.

Conclusions:

• UBE2M and UBE2F are significant contributors to tumor progression.
• Targeting UBE2M presents therapeutic potential through various mechanisms.
• Targeting UBE2F offers a strategy for enhancing chemo-/radiosensitivity by inducing apoptosis.